Heart Failure with Preserved Ejection Fraction,HFpEF
Conditions
Interventions
Treatment group:Fineridone 20mg every day for 12 months.
Sponsors
The Second People's Hospital of Foshan
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria for HFpEF as defined in the Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2025: (1) Have the epidemiological and population characteristics of HFpEF patients; (2) Have symptoms and/or signs of heart failure (such as dyspnea, decreased exercise tolerance, edema, etc.); (3) LVEF >=50% on cardiac imaging (mainly TTE); (4) Have objective evidence of cardiac structural and/or functional abnormalities consistent with left ventricular diastolic dysfunction and/or elevated left ventricular filling pressure. 2. New York Heart Association (NYHA) functional class II-IV, with symptoms and signs of heart failure. 3. Elevated NT-proBNP (>450 pg/mL for age 900 pg/mL for age 50-75 years, >1800 pg/mL for age >75 years) or B-type natriuretic peptide (BNP) >100 pg/mL. 4. Echocardiographic evidence of cardiac structural changes (such as increased left atrial size or left ventricular mass). 5. Age >=18 years.
Exclusion criteria
Exclusion criteria: 1. Patients with severe liver and kidney and other important organ disorders; 2. Patients with contraindications to the treatment and evaluation methods of this study; 3. Patients with acute and chronic infectious diseases; 4. Patients with acute decompensated heart failure; 5. Acute coronary syndrome occurred one month before screening, and coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting) or valve repair/replacement was performed; 6. Patients using finerenone within 1 month; 7. Patients with poor compliance. 8. BMI>50 kg/m^2.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peak time of myocardial segments (tpeak);Maximum ascending slope (Slopemax) of myocardial signal intensity;Peak signal intersity, SIpeak; | — |
Secondary
| Measure | Time frame |
|---|---|
| Left ventricular end diastolic diameter,LVEDD;Left ventricular ejection fraction ,LVEF;6-minute walking distance,6MWT;Minnesota Heart Failure Quality of Life Scale score,MHFQL;N-terminal pro-brain natriuretic peptide (NT-proBNP);Urinary microalbumin/urinary creatinine;Adverse event; | — |
Countries
China
Contacts
Public ContactZhang Zhenhong
The Second People's Hospital of Foshan
Outcome results
None listed